| 351 | SGHTSight Sciences, Inc. |
$77.4M |
-49.7% |
2025 |
| 352 | BNRBurning Rock Biotech Ltd |
$77.2M |
-10.3% |
2025 |
| 353 | CTMXCytomX Therapeutics, Inc. |
$76.2M |
-22.8% |
2025 |
| 354 | AUTLAutolus Therapeutics plc |
$75.4M |
-381.4% |
2025 |
| 355 | ABCLAbCellera Biologics Inc. |
$75.1M |
-194.9% |
2025 |
| 356 | RXRXRecursion Pharmaceuticals, Inc. |
$74.7M |
-863.4% |
2025 |
| 357 | ELMDElectromed, Inc. |
$73.8M |
15.3% |
2026 |
| 358 | CLLSCellectis S.A. |
$72.9M |
-92.7% |
2025 |
| 359 | CGENCompugen Ltd |
$72.8M |
48.6% |
2025 |
| 360 | BCYCBicycle Therapeutics PLC |
$72.6M |
-301.7% |
2025 |
| 361 | ASMBAssembly Biosciences, Inc. |
$72.3M |
-8.5% |
2025 |
| 362 | RCELAVITA Medical, Inc. |
$71.6M |
-67.8% |
2025 |
| 363 | VRDNViridian Therapeutics, Inc. |
$70.8M |
-483.6% |
2025 |
| 364 | FOCLEdap Tms SA |
$70.5M |
-41.5% |
2025 |
| 365 | BDTXBlack Diamond Therapeutics, Inc. |
$70M |
32.0% |
2025 |
| 366 | PSNLPersonalis, Inc. |
$69.6M |
-116.7% |
2025 |
| 367 | RMTIRockwell Medical, Inc. |
$69.3M |
-7.7% |
2025 |
| 368 | VIRVir Biotechnology, Inc. |
$68.6M |
-638.9% |
2025 |
| 369 | NTLAIntellia Therapeutics, Inc. |
$67.7M |
-609.9% |
2025 |
| 370 | KURAKura Oncology, Inc. |
$67.5M |
-412.9% |
2025 |
| 371 | SPROSpero Therapeutics, Inc. |
$66.8M |
12.8% |
2025 |
| 372 | XGNExagen Inc. |
$66.6M |
-30.0% |
2025 |
| 373 | CCMConcord Medical Services Holdings Ltd |
$65.9M |
-20.2% |
2025 |
| 374 | ENTAEnanta Pharmaceuticals Inc |
$65.3M |
-125.4% |
2025 |
| 375 | COSMCosmos Health Inc. |
$65.3M |
-29.3% |
2025 |
| 376 | FBIOFortress Biotech, Inc. |
$63.3M |
10.8% |
2025 |
| 377 | NUVBNuvation Bio Inc. |
$62.9M |
-325.3% |
2025 |
| 378 | TNGXTango Therapeutics, Inc. |
$62.4M |
-162.9% |
2025 |
| 379 | DERMJourney Medical Corp |
$61.9M |
-18.5% |
2025 |
| 380 | MHUAFMeihua International Medical Technologies Co., Ltd. |
$61.8M |
11.0% |
2025 |
| 381 | TRIBTrinity Biotech PLC |
$61.6M |
-51.6% |
2024 |
| 382 | CSBRChampions Oncology, Inc. |
$59.4M |
-2.0% |
2026 |
| 383 | APTAlpha Pro Tech Ltd |
$59.1M |
6.0% |
2025 |
| 384 | LNSRLENSAR, Inc. |
$58.4M |
-58.7% |
2025 |
| 385 | AYTUAytu Biopharma, Inc |
$57.6M |
-24.8% |
2026 |
| 386 | CVRXCVRx, Inc. |
$56.7M |
-94.1% |
2025 |
| 387 | NKTRNektar Therapeutics |
$55.2M |
-297.1% |
2025 |
| 388 | AGIOAgios Pharmaceuticals, Inc. |
$54M |
-764.0% |
2025 |
| 389 | QTTBQ32 Bio Inc. |
$53.7M |
55.5% |
2025 |
| 390 | IVVDInvivyd, Inc. |
$53.4M |
-98.2% |
2025 |
| 391 | APYXApyx Medical Corp |
$52.8M |
-21.2% |
2025 |
| 392 | PLXProtalix BioTherapeutics, Inc. |
$52.7M |
-12.5% |
2025 |
| 393 | IRIXIridex Corp |
$52.7M |
-8.4% |
2026 |
| 394 | OCULOcular Therapeutix, Inc |
$52M |
-511.9% |
2025 |
| 395 | CARLCarlsmed, Inc. |
$50.5M |
-58.7% |
2025 |
| 396 | LXRXLexicon Pharmaceuticals, Inc. |
$49.8M |
-101.1% |
2025 |
| 397 | GOSSGossamer Bio, Inc. |
$48.5M |
-351.5% |
2025 |
| 398 | SIShoulder Innovations, Inc. |
$47.3M |
-85.3% |
2025 |
| 399 | CAPSCapstone Holding Corp. |
$46.9M |
-45.3% |
2025 |
| 400 | PTGXProtagonist Therapeutics, Inc |
$46M |
-282.8% |
2025 |